This suggests that the composition of the microbiome is an important factor that can induce a response and 4D Pharma seeks to harness this knowledge. In this particular study 6 out of 15 of the patients who previously failed to respond subsequently experienced either tumor shrinkage or stable disease after the fecal transplant. A study published in the prestigious journal Science noted that metastatic melanoma patients who had previously not responded to checkpoint inhibitors could be converted to responders by receiving a fecal microbiota transplant. However, the data produced in immuno-oncology is impressive. Immuno-oncologyĤD Pharma is working across many therapeutic areas.

This article focuses on some of the most promising programs but is not a comprehensive overview of 4D Pharma’s pipeline. Given the impressive early data the company has produced in immuno-oncology and the vast pipeline, 4D Pharma which has a $240 million market cap appears undervalued when compared to peers. Data readouts in Covid-19 (Phase II), immuno-oncology including pancreatic cancer (Phase I/II) as well as a data readout for MRx-4DP0004 in asthma (Phase II) are expected in 2021. In addition to working in immuno-oncology, they are working on candidates in CNS, respiratory, autoimmune and GI indications.

Using the approach of matching the functions of single strains of bacteria with disease characteristics, 4D Pharma has compiled an extensive pipeline of live biotherapeutics. The bacteria exert their therapeutic effect as they are transported through the GI tract. The company approaches this challenge by deeply understanding the functioning of gut bacteria in order to utilize these functions. 4D Pharma (FRPRF) seeks to identify live bacteria that can be used as therapeutics.

4d pharma plc ft market